Hikma Pharmaceuticals (LON:HIK) Price Target Cut to GBX 2,510 by Analysts at Berenberg Bank

Key Points

• Berenberg Bank has reduced Hikma Pharmaceuticals' price target from GBX 2,560 to GBX 2,510, maintaining a "buy" rating with a potential upside of 41.65%.
• Four analysts currently rate Hikma Pharmaceuticals as a "buy," with an average consensus target price of GBX 2,615.
• Insider transactions indicate confidence in the company, with insiders acquiring 217,500 shares valued at over £380 million in the last quarter.

Hikma Pharmaceuticals (LON:HIK - Get Free Report) had its price objective cut by equities research analysts at Berenberg Bank from GBX 2,560 to GBX 2,510 in a note issued to investors on Thursday,Digital Look reports. The brokerage presently has a "buy" rating on the stock. Berenberg Bank's price objective suggests a potential upside of 41.65% from the company's current price.

Several other research analysts have also recently commented on the company. Jefferies Financial Group reissued a "buy" rating and set a GBX 2,600 target price on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. Deutsche Bank Aktiengesellschaft decreased their price objective on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Finally, JPMorgan Chase & Co. lowered their price objective on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an "overweight" rating for the company in a research report on Friday, August 8th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of GBX 2,615.

Hikma Pharmaceuticals Stock Performance

LON:HIK opened at GBX 1,772 on Thursday. Hikma Pharmaceuticals has a 52 week low of GBX 1,578 and a 52 week high of GBX 2,360. The company has a fifty day simple moving average of GBX 1,745.44 and a two-hundred day simple moving average of GBX 1,905.78. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The company has a market cap of £3.92 billion, a price-to-earnings ratio of 1,061.07, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Insider Buying and Selling

In other news, insider Laura Balan Balan acquired 3,500 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of GBX 1,821 per share, with a total value of £63,735. Also, insider Mazen Darwazah bought 14,000 shares of the business's stock in a transaction dated Tuesday, September 16th. The stock was acquired at an average cost of GBX 1,603 per share, for a total transaction of £224,420. In the last quarter, insiders acquired 217,500 shares of company stock valued at $380,015,500. 17.77% of the stock is owned by company insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.